These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24999802)

  • 41. Expression of PTEN and PTEN pseudogene in endometrial carcinoma.
    Yokoyama Y; Wan X; Shinohara A; Takahashi S; Takahashi Y; Niwa K; Tamaya T
    Int J Mol Med; 2000 Jul; 6(1):47-50. PubMed ID: 10851265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Digging for dead genes: an analysis of the characteristics of the pseudogene population in the Caenorhabditis elegans genome.
    Harrison PM; Echols N; Gerstein MB
    Nucleic Acids Res; 2001 Feb; 29(3):818-30. PubMed ID: 11160906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pseudogene-expressed RNAs: a new frontier in cancers.
    Shi X; Nie F; Wang Z; Sun M
    Tumour Biol; 2016 Feb; 37(2):1471-8. PubMed ID: 26662308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) as a novel plasma-based biomarker for hepatocellular carcinoma screening.
    Lui KY; Peng HR; Lin JR; Qiu CH; Chen HA; Fu RD; Cai CJ; Lu MQ
    Tumour Biol; 2016 Jan; 37(1):1253-60. PubMed ID: 26286832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methods for the Detection of Circulating Pseudogenes and Their Use as Cancer Biomarkers.
    Vaidya M; Sugaya K
    Methods Mol Biol; 2021; 2324():339-360. PubMed ID: 34165725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identifying large indels in targeted next generation sequencing assays for myeloid neoplasms: a cautionary tale of the
    Ng IK; Ng C; Low JJ; Chiu L; Seah E; Ng CH; Chng WJ; Yan B; Ban KHK
    J Clin Pathol; 2017 Dec; 70(12):1069-1073. PubMed ID: 28676493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular fossils in the human genome: identification and analysis of the pseudogenes in chromosomes 21 and 22.
    Harrison PM; Hegyi H; Balasubramanian S; Luscombe NM; Bertone P; Echols N; Johnson T; Gerstein M
    Genome Res; 2002 Feb; 12(2):272-80. PubMed ID: 11827946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feature selection and survival modeling in The Cancer Genome Atlas.
    Kim H; Bredel M
    Int J Nanomedicine; 2013; 8 Suppl 1(Suppl 1):57-62. PubMed ID: 24098079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CRISPR/Cas Technologies Applied to Pseudogenes.
    Vitiello M; Poliseno L
    Methods Mol Biol; 2021; 2324():265-284. PubMed ID: 34165721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of genes and pathways involved in kidney renal clear cell carcinoma.
    Yang W; Yoshigoe K; Qin X; Liu JS; Yang JY; Niemierko A; Deng Y; Liu Y; Dunker A; Chen Z; Wang L; Xu D; Arabnia HR; Tong W; Yang M
    BMC Bioinformatics; 2014; 15 Suppl 17(Suppl 17):S2. PubMed ID: 25559354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Iterative gene prediction and pseudogene removal improves genome annotation.
    van Baren MJ; Brent MR
    Genome Res; 2006 May; 16(5):678-85. PubMed ID: 16651666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer.
    Liu K; He L; Liu Z; Xu J; Liu Y; Kuang Q; Wen Z; Li M
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):472. PubMed ID: 29297280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types.
    Yang Y; Han L; Yuan Y; Li J; Hei N; Liang H
    Nat Commun; 2014; 5():3231. PubMed ID: 24488081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pseudofam: the pseudogene families database.
    Lam HY; Khurana E; Fang G; Cayting P; Carriero N; Cheung KH; Gerstein MB
    Nucleic Acids Res; 2009 Jan; 37(Database issue):D738-43. PubMed ID: 18957444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution of the NANOG pseudogene family in the human and chimpanzee genomes.
    Fairbanks DJ; Maughan PJ
    BMC Evol Biol; 2006 Feb; 6():12. PubMed ID: 16469101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prognostic signature of five pseudogenes for predicting lower-grade gliomas.
    Liu B; Liu J; Liu K; Huang H; Li Y; Hu X; Wang K; Cao H; Cheng Q
    Biomed Pharmacother; 2019 Sep; 117():109116. PubMed ID: 31247469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stage II oesophageal carcinoma: peril in disguise associated with cellular reprogramming and oncogenesis regulated by pseudogenes.
    Pravallika G; Rajasekaran R
    BMC Genomics; 2024 Feb; 25(1):135. PubMed ID: 38308202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.
    Yu L; Qiao R; Xu J; Han B; Zhong R
    Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive Detection of Pseudogenes Transcribed by Readthrough.
    Pinto R; Sobral D; Grosso AR
    Methods Mol Biol; 2021; 2324():85-102. PubMed ID: 34165710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.